Investors ask Allergan to nix Salix, negotiate with Valeant
This article was originally published in Scrip
Pershing Square Capital Management isn't the only investor pleading with Allergan to end its supposed negotiations to buy Salix Pharmaceuticals and begin discussions toward a merger with Valeant Pharmaceuticals.
You may also be interested in...
TVM, Focus/MD Anderson and RA Capital launched new venture capital funds. Also, LianBio’s $310m crossover financing, AavantiBio’s Sarepta-backed $107m series A and Sirnaomics’ $105m series D led recent VC rounds.
Amgen had a good third quarter despite some COVID-19 impacts but did not shed any light on filing plans for two key late-stage programs nor provide any insight into Phase III asthma results for tezepelumab.
Merck’s third quarter beat analyst consensus and the company raised its guidance. The COVID-19-battered vaccines business began to improve but Gardasil’s recovery was slower than expected.